| Caroline Baumal |
Caroline Baumal is currently the Chief Medical Officer at Apellis Pharmaceuticals, Inc. and a Professor at New England Eye Center. She holds a doctorate degree from the University of Toronto. |
| James G. Chopas |
James G. Chopas is currently the Chief Accounting Officer & VP-Controller at Apellis Pharmaceuticals, Inc. He previously worked as a Principal at PAREXEL International Corp., Ernst & Young LLP, and PricewaterhouseCoopers LLP. From 2011 to 2016, he was the Vice President-Finance at KBI Biopharma, Inc. He also served as the Chief Financial Officer, Treasurer, CAO & VP at Radius Health, Inc. from 2020 to 2021, and as the Chief Financial Officer at Cenduit LLC. Chopas received his graduate degree from Bentley University in 2000 and his undergraduate degree from the University of Massachusetts in 1988. |
| Lukas Scheibler |
Lukas Scheibler is currently the Chief Research Officer at Apellis Pharmaceuticals, Inc. He previously worked as the Head-Clinical Development at Novartis Corp. from 2002 to 2008. From 2011 to 2015, he served as the Vice President at Alcon Laboratories, Inc. Additionally, he held the position of Executive Vice President-Translational Medicine at Acucela, Inc. from 2015 to 2017. Dr. Scheibler obtained a graduate degree from the University of Basel and a doctorate degree from the University of Lausanne. |
| Mark DeLong |
Mark DeLong is currently the Chief Business & Strategy Officer at Apellis Pharmaceuticals, Inc. He previously worked at EMD Serono, Inc. as the Head of Business Development from 2007 to 2018. Mr. DeLong completed his undergraduate degree at The Pennsylvania State University and holds an MBA from the University of Michigan. |
| Ahmad Sadr |
Ahmad Sadr is currently the Vice President-Technical Operations at Apellis Pharmaceuticals, Inc. He previously worked as the Director-Outsourced Manufacturing at Portola Pharmaceuticals LLC from 2016 to 2017 and as the Vice President-Technical Operations at Vision Medicines, Inc. from 2015 to 2016. Mr. Sadr completed his undergraduate degree at the University of Maryland and his graduate degree at Widener University. |
| Nicole D. Perry |
Presently, Nicole D. Perry is Chief Accounting Officer & VP-Finance at Apellis Pharmaceuticals, Inc.
She previously held the position of Vice President-Finance at Revon Systems, Inc.
She received an undergraduate degree from the University of Oklahoma. |
| Adam Townsend |
Adam Townsend is currently the Chief Operating Officer at Apellis Pharmaceuticals, Inc. He previously worked as the Senior Vice President-Corporate Development at Biogen, Inc. from 2010 to 2018 and as the General Manager-UK, Ireland & Nordic Region at EUSA Pharma, Inc. from 2009 to 2010. Mr. Townsend completed his undergraduate degree at Royal Holloway University of London. |
| Jeffrey Eisele |
Jeffrey Eisele is currently the Chief Development Officer at Apellis Pharmaceuticals, Inc. Prior to this, he worked at Novartis, Inc. as the VP-Global Biostatistics & Head-Neuroscience. He completed his undergraduate degree at George Washington University and his graduate and doctorate degrees at the University of Michigan. |
| Nur Nicholson |
Currently, Nur Nicholson is Chief Technical Operations Officer at Apellis Pharmaceuticals, Inc.
In her past career she occupied the position of Head-Global Supply Chain at Alcon Laboratories, Inc. and VP-North American Business Operations at Galderma Laboratories LP.
Ms. Nicholson received an undergraduate degree from Middle East Technical University and an MBA from The Neeley School of Business. |
| Timothy Eugene Sullivan |
Timothy Eugene Sullivan is currently the Chief Financial Officer & Treasurer at Apellis Pharmaceuticals, Inc. He previously worked as a Director at Molecular Templates, Inc., an Independent Director at G1 Therapeutics, Inc., a Partner at Aju IB Investment Co., Ltd. (Private Equity), and as MD & Head-Life Sciences Investment Banking at Citizens Bank, NA (Providence, Rhode Island). He also served as Executive VP & Head-Corporate Development at Cornerstone Pharmaceuticals, Inc. Mr. Sullivan received his undergraduate degree from Harvard University and his MBA from Columbia Business School. |
| Alec Machiels |
Alec Machiels is the founder of Potentia Pharmaceuticals, Inc. (founded in 2001) where he holds the title of Director. He is also the founder of Apellis Pharmaceuticals, Inc. (founded in 2009) where he holds the title of Independent Director. Additionally, Mr. Machiels was the founder of Revon Systems, Inc. (founded in 2013) where he held the title of Director until 2019. Mr. Machiels currently holds multiple positions. He is the Chairman of Valero Peru SAC, Director of Policy Studies, Inc., Director of Valogix LLC, Director of Traxys SARL (since 2006), Director of Slipstream Communications LLC, and Co-Managing Partner of CoLift LLC (since 2021). In the past, Mr. Machiels served as Chairman of Creative Realities, Inc. (2014-2019), Director of Merisant Worldwide, Inc. (2005-2010), Director of Coffeyville Resources LLC (2003-2005), Director of Merisant Co. (2005-2008), Director of Neo Performance Materials (2008-2011), Director of Molycorp Minerals LLC, Director of Liberate Medical LLC, Analyst at Goldman Sachs International, Partner at Pegasus Capital Advisors LP, and Financial Analyst at Goldman Sachs & Co. LLC. He also served as a Trustee at the American Federation of Arts from 2010 to 2013. Mr. Machiels completed his graduate studies at Universität Konstanz and Katholieke Universiteit Leuven Law School. He also holds an MBA from Harvard Business School, which he obtained in 2001. |
| Pascal Deschatelets |
Pascal Deschatelets was the founder of Potentia Pharmaceuticals, Inc. where he held the title of Chief Operating Officer from 2001 to 2016. He is also the founder of Apellis Pharmaceuticals, Inc. and currently serves as the Chief Scientific Officer. Dr. Deschatelets is also the founder of Syntetica Fine Chemicals, Revon Systems, Inc... Dr. Deschatelets obtained a doctorate degree from the University of Montréal. |
| Federico Grossi |
Presently, Federico Grossi is Chief Medical Officer for Apellis Pharmaceuticals, Inc. He is also on the board of EndoProtech, Inc.
In his past career Dr. Grossi occupied the position of Director-Clinical Research at Potentia Pharmaceuticals, Inc., Executive Vice President at Potentia Pharmaceuticals, Inc. and Member-Face Transplant Team at the University of Louisville.
He received a graduate degree and a doctorate from the University of Louisville and a doctorate from National University of Cordoba. |
| Lok Chung Chan |
Lok Chung Chan founded Morningside Venture Investments Ltd. in 1986, Morningside Group Ltd. (United States) in 1986, Morningside Group Ltd. in 1986, where he is working as Chairman from 1986, and various other companies. Dr. Chan also currently works at Apellis Pharmaceuticals, Inc., as Chairman from 2013, Morningside College, as Chairman-Overseers Board, The Chinese University of Hong Kong, as Chairman, and various other companies. Dr. Chan also formerly worked at Inimex Pharmaceuticals, Inc., as Director, Vaccine Technologies, Inc., as Director, Critical Biologics Corp., as Director, and various other companies. Dr. Chan received his graduate degree and doctorate degree from Harvard University and undergraduate degree and graduate degree from the University of California, Los Angeles. |
| Karen Lewis |
Karen Lewis is currently the Chief People Officer at Apellis Pharmaceuticals, Inc. She previously worked as the Vice President-Finance at Advanced Media Corp. She obtained an undergraduate degree from Rider University. |
| Cedric Francois |
Cedric Francois is the founder of Potentia Pharmaceuticals, Inc. (founded in 2001) where he holds the title of Chief Executive Officer & Director. He is also the founder of Apellis Pharmaceuticals, Inc. (founded in 2009) where he holds the title of President, Chief Executive Officer & Director. Additionally, he is the founder of Revon Systems, Inc. (founded in 2013) where he holds the title of Director. Dr. Francois was also the founder of Liberate Medical LLC (founded in 2013) where he held the title of Director until 2019. Dr. Francois's current job(s) include being the Chairman of Somelor SASU since 2017, a Director at Acuamark Diagnostics, Inc. since 2021, and a Director at Louisville Healthcare CEO Council. In terms of education, Dr. Francois holds a doctorate degree from the University of Louisville and a doctorate degree from Katholieke Universiteit Leuven. |
| Stephanie Monaghan O'Brien |
Stephanie Monaghan O'Brien is an Independent Director at Apellis Pharmaceuticals, Inc. and a Director at 2020, Inc., Vigeo Therapeutics, Inc., Canopy Education, Inc., and Meissa Vaccines, Inc. She previously served as a Director at I-Behavior, Inc., ViOptix, Inc., Inimex Pharmaceuticals, Inc., BiddingForGood, Inc., Serica Technologies, Inc., Pinteon Therapeutics, Inc., Natural Polymer International Corp., and Alacer Biomedical, Inc. She was also the Lead Independent Director at Aduro BioTech, Inc. from 2011 to 2020. Ms. O'Brien started her career as a Principal at The Chase Manhattan Bank NA and Sohu.com, Inc. She received her graduate degree from New York University School of Law in 1985 and her undergraduate degree from Harvard College in 1980. |
| Paul R. Fonteyne |
Founder of Thyron Pharmaceuticals, Inc. and Allyx Therapeutics, Inc., Paul R. Fonteyne is a businessperson who has been at the head of 6 different companies and currently holds the position of Chairman at DalCor Pharmaceuticals Canada, Inc. and Chief Executive Officer of Thyron Pharmaceuticals, Inc. He is also on the board of 8 other companies.
Mr. Fonteyne previously held the position of Vice President-Sales of Merck & Co., Inc., Chairman, President, Chief Executive Officer & MD at Boehringer Ingelheim Corp., President & Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals, Inc., President of Boehringer Ingelheim Animal Health USA, Inc., Senior VP-Prescription Medicines Marketing at Boehringer Ingelheim GmbH, Chairman for National Pharmaceutical Council and Chairman-CEOs Against Cancer at American Cancer Society, Inc.
Paul R. Fonteyne received an MBA from Carnegie Mellon University and a graduate degree from Université Libre de Bruxelles. |
| Andrew Sinclair Dunlop |
Andrew Sinclair Dunlop is the founder of Epidarex Capital Partners LLC, which was founded in 2010. He is currently the Chairman of Inspiring Scotland, a Director at Potentia Pharmaceuticals, Inc., an Independent Director at Apellis Pharmaceuticals, Inc., and a Director at SIRAKOSS Ltd., Mironid Ltd., Edinburgh Molecular Imaging Ltd., and Reform Scotland Ltd. He previously held positions as a Director at MaxCyte, Inc. and MediQuest Therapeutics, Inc., a Non-Executive Director at enGene, Inc., an Associate at New Vantage Group LLC, and a Managing Partner at MASA Life Science Ventures. He also worked as a Business & Economics Analyst at the Center for Strategic & International Studies, Inc. Mr. Dunlop graduated from the University of Glasgow in 1994, the Maxwell School of Syracuse University in 1995, and received an MBA from Columbia Business School in 2000. |
